EGFR and colorectal carcinoma: A KRAS (Kirsten rat sarcoma viral oncogene)-activating mutation is a potent mechanism of resistance to EGFR inhibitors and occurs in around 40% of patients with advanced CRC, having a negative impact on overall survival (OS) [12].